Lonza (SGX:O6Z) posted strong performances across its CDMO business division during the first quarter of the year, according to a filing with the Singapore Exchange on Friday.

The Biologics segment showcased great momentum due to solid showing in the Mammalian and Bioconjugates divisions.

There was also a strong demand from the Cell & Gene division.

In its Outlook 2025, the pharmaceutical company expects 20% sales growth and a core EBITDA margin of about 30%.